Literature DB >> 2013430

Limitations of faecal chymotrypsin as a screening test for chronic pancreatitis.

L Riedel1, A R Walker, I Segal, A E Mohamed, A E Smyth, B Daya, I Naik.   

Abstract

Faecal chymotrypsin was measured in patients with chronic pancreatitis and in healthy black urban and rural control subjects. In the patients, significantly lower values of faecal chymotrypsin were obtained (mean (SD) 2.4 1.79 U/g stool) whereas in urban control subjects, values were within the normal range (mean (SD) 13.2 (11.9)). In rural black control subjects, however, the faecal chymotrypsin value was significantly lower (mean (SD) 7.1 (5.1)) than in urban black control subjects. It is suggested that faecal pH may influence faecal chymotrypsin values. The mean faecal pH in rural black subjects (pH 6.14) was significantly lower than that in urban control subjects (pH 6.77) and in patients with chronic pancreatitis (pH 6.61). Moreover, mean faecal chymotrypsin is high (20.0 U/g stool) at a pH greater than 7. Between pH 6 and 7 the mean value drops to 8.6 U/g stool and below pH 6 mean faecal chymotrypsin is in the abnormal range (4.4 U/g stool). Hence, low values for faecal chymotrypsin may be due to lower faecal pH (less than 6) in healthy control subjects. For diagnostic purposes, the faecal pH value should be determined if a low faecal chymotrypsin value is obtained.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2013430      PMCID: PMC1378844          DOI: 10.1136/gut.32.3.321

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  18 in total

1.  Fecal chymotrypsin: study on some characteristics of the enzyme.

Authors:  H K Dürr; R Schneider; C Bode; J C Bode
Journal:  Digestion       Date:  1978       Impact factor: 3.216

Review 2.  The interrelationships of the pancreatic enzymes.

Authors:  K G Wormsley; D M Goldberg
Journal:  Gut       Date:  1972-05       Impact factor: 23.059

3.  Effect of dietary fibre on stools and the transit-times, and its role in the causation of disease.

Authors:  D P Burkitt; A R Walker; N S Painter
Journal:  Lancet       Date:  1972-12-30       Impact factor: 79.321

4.  Trypsin and chymotrypsin in duodenal aspirate and faeces in response to secretin and cholecystokinin-pancreozymin.

Authors:  J K Sale; D M Goldberg; B Thjodleifsson; K G Wormsley
Journal:  Gut       Date:  1974-02       Impact factor: 23.059

5.  Bowel transit times in Bantu populations.

Authors:  A R Walker; B F Walker; B D Richardson
Journal:  Br Med J       Date:  1970-07-04

6.  Fate of trypsin and chymotrypsin in the human small intestine.

Authors:  D M Goldberg; R Campbell; A D Roy
Journal:  Gut       Date:  1969-06       Impact factor: 23.059

7.  A sensitive new substrate for chymotrypsin.

Authors:  E G DelMar; C Largman; J W Brodrick; M C Geokas
Journal:  Anal Biochem       Date:  1979-11-01       Impact factor: 3.365

8.  [Determination of chymotrypsin in feces as screening method for exocrine pancreatic insufficiency].

Authors:  J C Bode; H K Dürr
Journal:  Dtsch Med Wochenschr       Date:  1977-02-04       Impact factor: 0.628

9.  Chymotrypsin output in the stools in pancreatic and other diseases.

Authors:  T Gilat; E Gelman-Malachi; O Ronen
Journal:  Am J Gastroenterol       Date:  1976-08       Impact factor: 10.864

10.  Fecal chymotroypsin: a study on its diagnostic value by comparison with the secretin-cholecystokinin test.

Authors:  H K Dürr; M Otte; M M Forell; J C Bode
Journal:  Digestion       Date:  1978       Impact factor: 3.216

View more
  3 in total

1.  Impaired fecal elastase excretion in uremic pancreopathy.

Authors:  M Ventrucci; A Cipolla; M Middonno; C Racchini; P Simoni; K Afandi; F Grammatico; C Campieri
Journal:  Dig Dis Sci       Date:  2000-11       Impact factor: 3.199

Review 2.  Diagnosing early-stage chronic pancreatitis: is endoscopic ultrasound a reliable modality?

Authors:  Marc F Catalano
Journal:  J Gastroenterol       Date:  2007-01       Impact factor: 7.527

3.  Alterations of exocrine pancreas in end-stage renal disease. Do they reflect a clinically relevant uremic pancreopathy?

Authors:  M Ventrucci; C Campieri; M Di Stefano; G M Ubalducci; S Li Bassi; A Di Grazia; A Giudicissi; D Festi
Journal:  Dig Dis Sci       Date:  1995-12       Impact factor: 3.199

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.